Abstract
This review focuses on the current findings regarding interaction between amyloid β peptide (Aβ) and receptor for advanced glycation endproducts (RAGE) and its roles in the pathogenesis of Alzheimers disease (AD). As a ubiquitously expressed cell surface receptor, RAGE mediates the effects of Aβ on microglia, blood-brain barrier (BBB) and neurons through activating different signaling pathways. Data from autopsy brain tissues, in vitro cell cultures and transgenic mouse models suggest that Aβ-RAGE interaction exaggerates neuronal stress, accumulation of Aβ, impaired learning memory, and neuroinflammation. Blockade of RAGE protects against Aβ-mediated cellular perturbation. These findings may have an important therapeutic implication for neurodegenerative disorders relevant to AD.
Keywords: amyloid precursor protein, AD brains, neurofibrillary tangles, endothelin 1, blood-brain barrier
Current Molecular Medicine
Title: RAGE: A Potential Target for Aβ-Mediated Cellular Perturbation in Alzheimers Disease
Volume: 7 Issue: 8
Author(s): Shi Du Yan, Xi Chen, Douglas G. Walker, Ann Marie Schmidt, Ottavio Arancio and Lih-Fen Lue
Affiliation:
Keywords: amyloid precursor protein, AD brains, neurofibrillary tangles, endothelin 1, blood-brain barrier
Abstract: This review focuses on the current findings regarding interaction between amyloid β peptide (Aβ) and receptor for advanced glycation endproducts (RAGE) and its roles in the pathogenesis of Alzheimers disease (AD). As a ubiquitously expressed cell surface receptor, RAGE mediates the effects of Aβ on microglia, blood-brain barrier (BBB) and neurons through activating different signaling pathways. Data from autopsy brain tissues, in vitro cell cultures and transgenic mouse models suggest that Aβ-RAGE interaction exaggerates neuronal stress, accumulation of Aβ, impaired learning memory, and neuroinflammation. Blockade of RAGE protects against Aβ-mediated cellular perturbation. These findings may have an important therapeutic implication for neurodegenerative disorders relevant to AD.
Export Options
About this article
Cite this article as:
Yan Du Shi, Chen Xi, Walker G. Douglas, Schmidt Marie Ann, Arancio Ottavio and Lue Lih-Fen, RAGE: A Potential Target for Aβ-Mediated Cellular Perturbation in Alzheimers Disease, Current Molecular Medicine 2007; 7 (8) . https://dx.doi.org/10.2174/156652407783220741
DOI https://dx.doi.org/10.2174/156652407783220741 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Knowledge on Molecular Components of Lewy Bodies Discloses Future Therapeutic Strategies in Parkinsons Disease
Current Drug Targets - CNS & Neurological Disorders Neural Stem Cells and Human Induced Pluripotent Stem Cells to Model Rare CNS Diseases
CNS & Neurological Disorders - Drug Targets Pharmacotherpy and Alzheimer’s Disease: The M-Drugs (Melatonin, Minocycline, Modafinil, and Memantine) Approach
Current Pharmaceutical Design Tacrine Derivatives and Alzheimers Disease
Current Medicinal Chemistry Protein Misfolding Diseases and Therapeutic Approaches
Current Protein & Peptide Science Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System
Current Pharmaceutical Design Age-Related Increase in Levels of 5-Hydroxymethylcytosine in Mouse Hippocampus is Prevented by Caloric Restriction
Current Alzheimer Research Cytochrome P450s: Mechanisms and Biological Implications in Drug Metabolism and its Interaction with Oxidative Stress
Current Drug Metabolism L-Dopa Prodrugs: An Overview of Trends for Improving Parkinsons Disease Treatment
Current Pharmaceutical Design Drugs Used to Treat Parkinsons Disease, Present Status and Future Directions
CNS & Neurological Disorders - Drug Targets Huntingtons Disease: The Value of Transcranial Meganetic Stimulation
Current Medicinal Chemistry Gene Therapy for Parkinsons Disease: Progress and Challenges
Current Gene Therapy Moving to the Rhythm with Clock (Circadian) Genes, Autophagy, mTOR, and SIRT1 in Degenerative Disease and Cancer
Current Neurovascular Research Long-Term Exposure to Ambient Hydrocarbons Increases Dementia Risk in People Aged 50 Years and above in Taiwan
Current Alzheimer Research Apo-E4 Allele in Conjunction with Aβ42 and Tau in CSF: Biomarker for Alzheimers Disease
Current Alzheimer Research A Multicenter, Double-Blind, Placebo-Controlled Trial of the PDE9A Inhibitor, PF-04447943, in Alzheimer's Disease
Current Alzheimer Research The Effects of Italian Mediterranean Organic Diet (IMOD) on Health Status
Current Pharmaceutical Design Is Alpha-Synuclein Pathology a Target for Treatment of Neurodegenerative Disorders?
Current Alzheimer Research Nicotinamide as a Foundation for Treating Neurodegenerative Disease and Metabolic Disorders
Current Neurovascular Research Chemopreventive Properties of Peptide Lunasin: A Review
Protein & Peptide Letters